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Treatment Options for Acute Massive Pulmonary Embolism
Lawrence Lee PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND 58202-9037

Abstract
 Acute massive pulmonary embolism is characterized by
obstruction of the pulmonary arterial tree that exceeds 50% of the
cross-sectional area causing acute and severe cardiopulmonary
failure from right ventricular overload.
• Systemic thrombolytic therapy is recommended as standard, firstline treatment in patients with massive pulmonary embolism
unless contraindicated and catheter directed therapies, including
low dose thrombolytic administration directly into thrombus and
mechanical thrombectomy can be adjunctive or used as an
alternative to systemic treatments.
• This literature review researched articles looking at both systemic
thrombolysis and endovascular techniques for the treatment of
acute massive pulmonary embolism with an emphasis on long
term clinical outcomes.
• Study results demonstrated the efficacy and safety of systemic
thrombolysis and catheter directed therapies as well as adverse
effects; however, further randomized trials are needed, as
acknowledged by many of the authors included in this paper,
comparing both treatment options for hemodynamically unstable
patients with emphasis on long term sequalae.

Introduction
• Systemic thrombolysis is standard, first-line treatment for a
patient presenting with hemodynamically unstable pulmonary
embolism, but data from randomized trials using catheter directed
techniques is gaining attention as a viable option for patients who
have contraindications to high-dose systemic thrombolysis

Statement of the Problem
• Deciding on a treatment plan for a patient presenting with an
acute massive pulmonary embolism can be challenging for some
clinicians. Systemic thrombolytic therapy continues to be
standard, first-line therapy, but new technologies using catheter
directed techniques with a combination of thrombectomy and
intraclot thrombolysis are demonstrating safety and efficacy and
are gaining support in the medical community.

Research Questions
• In patients presenting with acute massive pulmonary embolism,
how does the use of systemic thrombolytics compare in efficacy
and safety over catheter directed therapies?
• Is there improvement in quality of life, dyspnea, and functional
capacity with catheter directed thrombolysis and thrombectomy
compared to systemic thrombolysis?

• The ELOPE (Evaluation of Long-term Outcomes after PE) cohort
study provided new information on prognosis following
pulmonary embolism ( Kahn et al., 2017).
• Data provided by Kahn et al. (2014) did show chronic
thromboembolic pulmonary hypertension was found to range
from 1 to 4% with a poor prognosis and a median survival of 1224 months.

Literature Review
Pathology of Pulmonary Embolism
• Thrombus occurs when there is a disruption in the mechanisms
between blood coagulation and anticoagulation, and PE can
follow when thrombus from a deep vein thrombosis (DVT)
breaks off and travels to the pulmonary circulation, although nonthrombotic material like fat, tumor or air can also be the source
(Giordano, Jansson, Young, Hogan, & Kabrhel, 2017).
• If the DVT forms in a large vessel, it is more likely to dislodge
and embolize the pulmonary artery occluding some degree of the
vasculature.
• Large thrombi can straddle the bifurcation or obstruct the entire
pulmonary outflow tract, increasing the strain on the right heart
and leading to severe hypotension and death (Giordano, Jansson,
Young, Hogan, & Kabrhel, 2017).
Treatment Options for Pulmonary Embolism
• Depends on the hemodynamic stability of the patient and the clot
burden.
• Therapy consists of anticoagulation, systemic thrombolytics and
endovascular therapies including mechanical thrombectomy and
intraclot thrombolysis (Chechi et al., 2009).
• Systemic thrombolysis is standard, first-line treatment with low
risk for major hemorrhage in selected patients.
• Catheter directed therapies, including low dose thrombolytic
administration directly into thrombus and mechanical
thrombectomy can be adjunctive or used as an alternative to
systemic treatments.
Safety of Systemic and Endovascular Therapy
• Major and minor bleeding remain a concern when using
thrombolytics even though evidence suggest these agents dissolve
clots more rapidly than heparin and reduce the death rate
associated with PE (Hao, Dong, Yue, & Liu, 2015).
• Systemic thrombolysis demonstrates an increased risk of
hemorrhage when compared to catheter directed intraclot lytics
(Kuo et al., 2009).
• A meta-analysis conducted by Bloomer et al. (2017),
demonstrated low bleeding complications with CDT
Long Term Sequela
• When treating hemodynamically unstable patients presenting with
pulmonary embolism, it’s important to consider not only the
immediate threat, but also long term sequela like quality of life
(Kahn et al., 2017).
• Hemodynamically unstable patients may not do well once
diagnosed and treated for massive pulmonary embolism (Kahn et
al., 2014).

Applicability to Clinical
Practice
• Diagnosis of PE uses a combination of techniques including a D
dimer, CTA and scoring systems like Geneva, Wells, and Miniati
and studies have demonstrated a low probability of pulmonary
embolism if the D-dimer is normal and the scoring system used
shows a low probability. This is important data for clinicians
working in rural areas where access to CTA might not be available.
• The efficacy and safety of both systemic and catheter directed
therapies appears comparable depending on which study you read,
especially looking at short term outcomes.
• Several studies have looked at long-term sequela post pulmonary
embolism and the role residual thrombus plays in quality of life
measures. The clinical significance of residual pulmonary vascular
abnormalities continues to be poorly understood but there is
agreement that these patients may not do well long-term due to
chronic thromboembolic pulmonary hypertension.

• Improvement in obstruction, perfusion, Miller indexes, and
systolic pulmonary artery pressure before and after rheolytic
thrombectomy according to hemodynamic compromise (i.e.,
shock, red bars; hypotension, green bars; right ventricular
dysfunction, blue bars) Chechi et al. (2009).

Discussion
• As the first line treatment for hemodynamically unstable patients
presenting with pulmonary embolism, systemic thrombolysis is
well tolerated and efficacious; however, it may be contraindicated
in patients with prior intracranial hemorrhage, cerebral vascular
lesions, malignancy, active bleeding, bleeding diathesis or in
patients older than 65.
• Systemic thrombolytics remains the gold standard for treatment
of massive PE for patients without contraindications.
• Catheter directed therapies allow for both low dose intraclot
thrombolytics and mechanical thrombectomy and may prove
beneficial for the long-term sequela related to massive thrombus.
• Chronic thromboembolic pulmonary hypertension can be found in
a small percentage of patients post pulmonary embolism which
carries a poor prognosis and although the clinical significance of
residual pulmonary vascular abnormalities continues to be poorly
understood, the literature review determined that patients may not
do well long term once diagnosed and treated with thrombolytics
(Kahn et al., 2014).
• Chronic thromboembolic pulmonary hypertension was found to
range from 1 to 4% with a poor prognosis and a median survival
of 12-24 months (Kahn et al., 2017).
• The question of what is the best treatment option for patients
presenting with hemodynamically unstable massive pulmonary
embolism was not definitively answered in my review of the
literature and shows that further prospective research, comparing
systemic thrombolytic therapy to catheter directed treatments to
include long-term outcomes, is indicated.
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